These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical correlates and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous stem cell transplantation lenalidomide maintenance therapy. Wudhikarn K; Padrnos L; Lasho T; LaPlant B; Kumar S; Dispenzieri A; Lacy M; Rajkumar SV; Gertz M; Mangaonkar AA; Gonsalves W; Ketterling R; Shi CX; Fonseca R; Stewart AK; Patnaik MM Am J Hematol; 2021 May; 96(5):E157-E162. PubMed ID: 33580975 [No Abstract] [Full Text] [Related]
5. Impact of frailty, melphalan pharmacokinetics, and pharmacogenetics on outcomes post autologous hematopoietic cell transplantation for multiple myeloma. Nampoothiri RV; Kasudhan KS; Patil AN; Malhotra P; Khadwal A; Prakash G; Jain A; Malhotra S; Verma Attri S; Varma N; Varma S; Lad DP Bone Marrow Transplant; 2019 Dec; 54(12):2088-2095. PubMed ID: 31406224 [TBL] [Abstract][Full Text] [Related]
6. High-dose melphalan in 1 day versus over 2 days followed by autologous stem cell transplantation as consolidation treatment in patients with multiple myeloma. Aydin M; Tang MW; Wondergem MJ; de Leeuw DC; Wegman JJ; Biemond BJ; van de Donk NWCJ; Zweegman S; Meijer E; Nur E Br J Haematol; 2022 Mar; 196(6):e67-e70. PubMed ID: 34961917 [No Abstract] [Full Text] [Related]
7. [Efficacy and safety of autologous hematopoietic stem cell transplantation pretreated with Melphalan hydrochloride for injection in the treatment of 125 cases of multiple myeloma]. Huang WY; Liu W; Liu HM; Xu Y; Wang Q; Du CX; Xiong WJ; Sui WW; Tian F; Wang J; Yi SH; An G; Qiu LG; Zou DH Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):148-150. PubMed ID: 36948870 [No Abstract] [Full Text] [Related]
8. [Multiple Myeloma: from Diagnosis to the Up-to-date Treatment. Topics: VII. Hematopoietic Stem Cell Transplantation for Multiple Myeloma]. Nakaseko C Nihon Naika Gakkai Zasshi; 2016 Jul; 105(7):1246-54. PubMed ID: 30168969 [No Abstract] [Full Text] [Related]
9. Microbiota dysbiosis after high-dose melphalan and autologous hematopoietic cell transplantation in multiple myeloma. Malard F; Battipaglia G; Gaugler B; Siblany L; van de Wyngaert Z; Bonnin A; Duléry R; Banet A; Stocker N; Ricard L; Brissot E; Mohty M Bone Marrow Transplant; 2023 Nov; 58(11):1275-1278. PubMed ID: 37608072 [No Abstract] [Full Text] [Related]
10. Autologous Hematopoietic Cell Transplantation for Dialysis-Dependent Myeloma: More Efficient, Less Toxic. Amit O; Ram R Acta Haematol; 2018; 139(2):104-105. PubMed ID: 29414800 [No Abstract] [Full Text] [Related]
11. Peripheral flow-MRD status at the time of autologous stem cell collection predicts outcome in multiple myeloma. Moor I; Bacher VU; Jeker B; Taleghani BM; Mueller BU; Keller P; Betticher D; Egger T; Novak U; Pabst T Bone Marrow Transplant; 2018 Dec; 53(12):1599-1602. PubMed ID: 29884856 [No Abstract] [Full Text] [Related]
12. Melphalan pharmacokinetics and transplant related toxicity during autologous stem cell transplantation. Sahin U; Soydan E; Gokmen A; Ozcan M; Arslan O Bone Marrow Transplant; 2021 Jan; 56(1):7-8. PubMed ID: 32848191 [No Abstract] [Full Text] [Related]
13. Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation - a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients. Rundgren IM; Ersvær E; Ahmed AB; Ryningen A; Bruserud Ø BMC Immunol; 2019 Nov; 20(1):39. PubMed ID: 31703617 [TBL] [Abstract][Full Text] [Related]
14. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Srour SA; Milton DR; Bashir Q; Nieto Y; Saini N; Daher M; Ramdial J; Im J; Hosing C; Delgado R; Manasanch E; Lee HC; Thomas S; Kaufman G; Patel K; Popat U; Weber D; Orlowski R; Shpall E; Champlin RE; Qazilbash MH Haematologica; 2021 Dec; 106(12):3211-3214. PubMed ID: 34407606 [No Abstract] [Full Text] [Related]
15. The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant. Manjappa S; Fiala MA; King J; Kohnen DA; Vij R Bone Marrow Transplant; 2018 Nov; 53(11):1483-1486. PubMed ID: 29795420 [No Abstract] [Full Text] [Related]
16. Response to "Conditioning with melphalan (Mel) 200 mg/m Caravita di Toritto T; Rago A Eur J Haematol; 2023 Feb; 110(2):221. PubMed ID: 36300853 [No Abstract] [Full Text] [Related]
17. Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial. Respond to author. Zhang K; Gao C; Tang Q Support Care Cancer; 2019 Sep; 27(9):3171-3172. PubMed ID: 30868268 [No Abstract] [Full Text] [Related]
18. Myeloma, melphalan, and the taste of transplantation. Banerjee R Cancer; 2022 Nov; 128(21):3784-3786. PubMed ID: 36041229 [No Abstract] [Full Text] [Related]
19. Still learning the right way to administer melphalan in autologous transplantation. Lad DP; Patil AN; Malhotra P Bone Marrow Transplant; 2020 Dec; 55(12):2357-2358. PubMed ID: 32523051 [No Abstract] [Full Text] [Related]